Sheep and Goat Pox Vaccines Market Report 2025

The sheep and goat pox vaccines market size has grown steadily in recent years. It will grow from $57.79 billion in 2024 to $60.58 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to increased outbreaks of sheep and goat pox, government vaccination programs, advancements in veterinary medicine, high mortality rates in livestock, increased awareness among farmers, economic losses due to disease, trade restrictions on affected areas, improved diagnostic techniques, the historical prevalence of the disease, and collaboration between veterinary institutions.

The sheep and goat pox vaccines market size is expected to see steady growth in the next few years. It will grow to $72.47 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to the growing demand for livestock products, expanding livestock farming, government subsidies for vaccines, rising investment in veterinary research, technological advancements in vaccine production, increasing awareness of animal health, international trade agreements, climate change impacting disease patterns, the emergence of new vaccine technologies, economic growth in developing regions. Major trends in the forecast period include the development of multivalent vaccines, increasing use of recombinant vaccines, growing focus on vaccine safety, rise in public-private partnerships, expansion of veterinary vaccine market, digital tracking of vaccination programs, increased funding for animal health research, regional disease eradication initiatives, growing adoption of sustainable farming practices, enhanced regulatory frameworks for vaccines.

The increasing demand for livestock products is poised to drive growth in the market for sheep and goat pox vaccines. Livestock products encompass various goods derived from domesticated animals raised in agricultural settings. This rising demand stems from factors such as income and population growth, urbanization, health considerations, evolving consumer preferences, globalization, trade, and economic development. Sheep and goat pox vaccines play a crucial role in protecting livestock products by preventing disease outbreaks and ensuring the health and productivity of sheep and goat populations. For example, in February 2024, the Department for Environment, Food, and Rural Affairs noted an increase in red meat production, particularly mutton and lamb, with the largest rise recorded at 2.9%. Additionally, total domestic fish production in 2022 slightly exceeded 4.18 billion metric tons, up from 4.17 billion metric tons in 2020. Hence, the growing demand for livestock products is expected to drive expansion in the sheep and goat pox vaccines market.

Major companies in the sheep and goat pox vaccine market are concentrating on the development of innovative products, such as live attenuated vaccines, to improve immune responses while minimizing side effects. Live attenuated vaccines contain live viruses or bacteria that have been weakened in the laboratory to prevent them from causing disease in healthy individuals. These vaccines stimulate a strong immune response by simulating a natural infection without causing illness. For example, in August 2022, the Indian Council of Agricultural Research, based in India, developed Lumpi-ProVacInd to fight Lumpy Skin Disease (LSD) in cattle. This vaccine is intended for preventive immunization, providing immunity for at least one year with a single dose that contains 103.5 TCID50 of the attenuated LSD virus. It is safe for animals, induces a strong immune response, and must be stored at 4°C, requiring careful handling during transportation and use.

In September 2022, Hester Biosciences Limited, an India-based animal healthcare company, acquired the manufacturing technology for the Goat Pox vaccine (Uttarkashi Strain) from the Indian Veterinary Research Institute (IVRI) for an undisclosed sum. This acquisition enables Hester to supply the goat pox vaccine through state government tenders for cattle immunization against lumpy skin disease in various states. The Indian Veterinary Research Institute, a prominent institution for livestock research and development in India, facilitated this technology transfer.

Major companies operating in the sheep and goat pox vaccines market are Indian Immunologicals Ltd., Kemin Industries, Bimeda Biologicals, Hester Biosciences Limited, Dollvet, MSD Animal Health, MCI Santé Animale, Creative Biolabs, Biovex Inc., Advacare Pharma, Brilliant Bio Pharma Private Limited, Intervac (PVT) Ltd., Agrinnovate India Limited, Bio-Med Pvt Limited, JOVAC, Vetal Animal Health Products, Kenya Veterinary Vaccines Production Institute, Vedall Pharma Private Limited, Farmer's Pharma Private Limited, Institute of Veterinary Biological Products.

North America was the largest region in the sheep and goat pox vaccines market in 2024. The regions covered in the sheep and goat pox vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sheep and goat pox vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Sheep and goat pox vaccines are specifically developed to prevent diseases caused by viruses belonging to the Capripoxvirus genus, which include sheep pox and goat pox. These vaccines play a critical role in preventing and managing outbreaks among sheep and goat populations, as both diseases can lead to significant economic losses due to high mortality rates and reduced productivity. They function by stimulating the immune system to generate antibodies against the viruses, thereby providing protection from infection.

The primary types of sheep and goat pox vaccines include live attenuated vaccines, inactivated vaccines, and others. Live attenuated vaccines use weakened forms of the virus to stimulate the immune system without causing severe illness. They are particularly effective for diseases such as sheep and goat pox where a robust immune response is necessary for effective protection. These vaccines are administered via various routes such as injectable and intranasal applications for sheep and goats.

The sheep and goat pox vaccines research report is one of a series of new reports that provides sheep and goat pox vaccines market statistics, including the sheep and goat pox vaccines industry's global market size, regional shares, competitors with a sheep and goat pox vaccines market share, detailed sheep and goat pox vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the sheep and goat pox vaccines industry. This sheep and goat pox vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The sheep and goat pox vaccines market consists of sales of recombinant vaccines and subunit vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.